Episodic therapy for genital herpes in Sub-Saharan Africa: A pooled analysis from three randomized controlled trials

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Weiss, Helen A ^a   Bailey, Gabriela ^b   Phiri, Sam ^c   Gresenguet, Gerard ^d   LeGoff, Jerome ^e   Pepin, Jacques ^f   Lewis, David A ^a,g,h   Belec, Laurent ^e   Hoffman, Irving F ⁱ   Miller, William C ⁱ   Mayaud, Philippe ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Guatemala and Tephinet Inc   (Guatemala)

^c LIGHTHOUSE TRUST   (Malawi)

^d Centre National de Référence pour les Maladies Sexuellement Transmissibles   (Central African Republic)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITÉ DE SHERBROOKE   (Canada)

^g NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; PLACEBO; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; FEMALE; GENITAL HERPES; GENITAL ULCER; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOGRANULOMA VENEREUM; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOUTH AFRICA; SYMPTOM; SYPHILIS; TREATMENT DURATION; TREATMENT RESPONSE; ULCER HEALING; ULCUS MOLLE; ADOLESCENT; AFRICA SOUTH OF THE SAHARA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; ULCER; VIROLOGY;

HERPES; HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 1;

ACYCLOVIR; ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; FEMALE; HERPES GENITALIS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; RNA, VIRAL; ULCER; YOUNG ADULT;

EID: 79960713619     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022601     Document Type: Article

References (28)

1. Weiss H, (2004) Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 11 (Suppl 1): 24A-35A.
2. Corey L, Adams HG, Brown ZA, Holmes KK, (1983) Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 98: 958-972.
3. Reichman RC, Badger GJ, Mertz GJ, Corey L, Richman DD, et al. (1984) Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 251: 2103-2107.
4. Mertz GJ, Critchlow CW, Benedetti J, Reichman RC, Dolin R, et al. (1984) Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA 252: 1147-1151.
5. Organization WH (2003) Guidelines for the management of sexually transmitted infections Geneva World Health Organization ISBN 92 4 154626 3 ISBN 92 4 154626 3.
6. Corbell C, Stergachis A, Ndowa F, Ndase P, Barnes L, et al. (2010) Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries. Sex Transm Dis 37: 488-493.
7. Mayaud P, Legoff J, Weiss HA, Gresenguet G, Nzambi K, et al. (2009) Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. J Infect Dis 200: 216-226.
8. Phiri S, Hoffman IF, Weiss HA, Martinson F, Nyirenda N, et al. (2010) Impact of aciclovir on ulcer healing, lesional, genital and plasma HIV-1 RNA among patients with genital ulcer disease in Malawi. Sex Transm Infect 86: 345-352.
9. Paz-Bailey G, Sternberg M, Puren AJ, Markowitz LE, Ballard R, et al. (2009) Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. J Infect Dis 200: 1039-1049.
10. Lewis DA, Marumo E, (2010) Revision of the national guideline for first-line comprehensive management and control of sexually transmitted infections: what's new and why? SA Fam Pract 52: 20-24.
11. Zou G, (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159: 702-706.
12. Celum C, Levine R, Weaver M, Wald A, (2004) Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ 82: 447-453.
13. Corey L, (2007) Synergistic copathogens-HIV-1 and HSV-2. N Engl J Med 356: 854-856.
14. Glynn JR, Biraro S, Weiss HA, (2009) Herpes simplex virus type 2: a key role in HIV incidence. AIDS 23: 1595-1598.
15. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, et al. (2008) Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 358: 1560-1571.
16. Celum C, Wald A, Hughes J, Sanchez J, Reid S, et al. (2008) Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371: 2109-2119.
17. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, et al. (2010) Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 362: 427-439.
18. Dunne EF, Whitehead S, Sternberg M, Thepamnuay S, Leelawiwat W, et al. (2008) Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 49: 77-83.
19. Cowan FM, Pascoe SJ, Barlow KL, Langhaug LF, Jaffar S, et al. (2008) A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect 84: 548-553.
20. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. (2007) Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 196: 1500-1508.
21. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. (2009) HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS 23: 479-483.
22. Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, et al. (2008) Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 198: 1804-1808.
23. Tanton C, Weiss HA, Rusizoka M, Legoff J, Changalucha J, et al. (2010) Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial. J Infect Dis 201: 1285-1297.
24. Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, et al. (2009) Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 23: 461-469.
25. Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, et al. (2010) Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 375: 824-833.
26. Ioannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, et al. (1998) Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 178: 349-359.
27. Strick LB, Wald A, Celum C, (2006) Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis 43: 347-356.
28. Langenberg A, Benedetti J, Jenkins J, Ashley R, Winter C, et al. (1989) Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med 110: 882-887.